Combining pioneering iPSC technology and patented live cell bioimaging, LumiSTAR is opening up exciting new possibilities in the treatment of various diseases and the development of innovative new dru ...

Sean "Diddy" Combs desire to push back his criminal trial fell short today as a federal judge is determined to get things going by early May.

Another reason for choosing a particular modality is that it is a team’s specialty. Strategic choices can be less about ...

A new method demonstrated by chemists at the University of Chicago shows how to build certain molecules much more efficiently ...

A new discovery could pave the way for more effective cancer treatment by helping certain drugs work better inside the body.

Interested in finding a better way to develop drugs to treat amyotrophic lateral sclerosis (ALS), Northeastern researcher ...

Immunome's strong financial position supports ongoing clinical development and potential market entry for key assets. See why ...

ProFuse's novel technology addresses the growing need to preserve muscle in the face of aging and the popularity of ...

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

Choosing between plate reader-based assays and mass spectrometry solutions is a key decision for scientists when evaluating ...

Protagonist Therapeutics, Inc. (”Protagonist” or the “Company”), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that ...

CMND-100 is Clearmind’s proprietary MEAI-based oral drug candidate, developed as a potential breakthrough treatment for AUD. Unlike traditional treatment methods, CMND-100 is designed to offer a novel ...